CMMB - Chemomab Therapeutics Ltd.

QQQ $ 469.22 $ 0.00 (0 %)

DIA $ 409.73 $ 1.01 (0.25 %)

SPY $ 554.79 $ 5.63 (1.03 %)

TLT $ 100.61 $ -0.08 (-0.08 %)

GLD $ 232.25 $ -0.37 (-0.16 %)

Previous Close

$ 2.03

Open

Bid

$ 2.02 x 400

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 0.42 - $ 2.55

Volume

211,798

Average Volume

Market Cap

115.34M

Beta (5Y Monthly)

$ 1.53

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-11-2023	03-31-2023	10-Q
2	03-20-2023	12-31-2022	10-K
3	11-10-2022	09-30-2022	10-Q
4	08-12-2022	06-30-2022	10-Q
5	05-12-2022	03-31-2022	10-Q
6	03-30-2022	12-31-2021	10-K
7	11-12-2021	09-30-2021	10-Q
8	08-13-2021	06-30-2021	10-Q
9	05-13-2021	03-31-2021	10-Q
10	03-09-2021	12-31-2020	10-K
11	11-16-2020	09-30-2020	10-Q
12	08-14-2020	06-30-2020	10-Q
13	05-07-2020	03-31-2020	10-Q
14	03-17-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

why-recursion-pharmaceuticals-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Recursion Pharmaceuticals Shares Are T...
09/03/2024 17:41:09

Chemomab Says Existing Liquidity Resources...
08/21/2024 11:09:15

Chemomab Therapeutics Q2 2024 GAAP EPS $(0...
08/21/2024 11:07:02

Chemomab Therapeutics Regains Compliance W...
07/26/2024 11:08:56

Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was not in compliance with the mi...

chemomab-therapeutics-reveals-data-from-mid-stage-study-for-liver-disease-candidate-stock-plunges-on-capital-raise

Chemomab Therapeutics Reveals Data From Mi...
07/25/2024 17:53:09

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing saf...

Chemomab Therapeutics Announces Private Pl...
07/25/2024 11:47:29

Pursuant to the terms of the securities purchase agreement, the Company is selling to certain investors (i) 4,188,867 Americ...

Chemomab Therapeutics Reported Topline Res...
07/25/2024 11:45:39

CHEMOMAB Granted U.S. Patent #12018074: An...
06/25/2024 19:43:35

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12018074

Chemomab Says It Presented Two Scientific ...
06/06/2024 11:22:44

Maxim Group Initiates Coverage On Chemomab...
05/13/2024 16:32:41

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and annou...

Chemomab Therapeutics Q1 2024 GAAP EPS $(0...
05/09/2024 11:10:07

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share. This is a 65 percent increase over losses o...

Chemomab Therapeutics Granted 180-Day Exte...
05/08/2024 11:15:39

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
05/06/2024 16:31:16

Oppenheimer Upgrades Chemomab Therapeutics...
05/06/2024 11:52:09

Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Outperform and announces $6 pric...

Chemomab Reports New Peer-Reviewed Publica...
04/18/2024 11:11:35

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), ...

Chemomab shares are trading higher after t...
03/25/2024 11:19:45

Chemomab Bagged New European Patent for CM...
03/25/2024 11:09:46

Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics...

Oppenheimer Maintains Perform on Chemomab ...
03/08/2024 13:45:49

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Perform.

Chemomab Therapeutics Q4 EPS $(0.26) Up Fr...
03/07/2024 12:06:29

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losse...

Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...